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An international multicentre study of first and second primary neoplasms associated with male breast cancer was carried out by
pooling data from 13 cancer registries. Among a total of 3409 men with primary breast cancer, 426 (12.5%) developed a second
neoplasia; other than breast cancer, a 34% overall excess risk of second primary neoplasia, affecting the small intestine (standardised
incidence ratio, 4.95, 95% confidence interval, 1.35–12.7), rectum (1.78, 1.20–2.54), pancreas (1.93, 1.14–3.05), skin (nonmelanoma,
1.65, 1.16–2.29), prostate (1.61, 1.34–1.93) and lymphohaematopoietic system (1.63, 1.12–2.29). A total of 225 male breast
cancers was recorded after cancers other than breast cancer, but an increase was found only after lymphohaematopoietic neoplasms.
BRCA2 (and to some extent BRCA1) mutations may explain the findings for pancreatic and prostate cancers. Increases at other sites
may be related to unknown factors or to chance. This large study shows that the risks for second discordant tumours after male
breast cancer pose only a moderate excess risk.
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It is well established that women with a first primary breast cancer
run a 2–5-fold increased risk of developing second primary breast
cancer compared with the risk for the first primary breast cancer
(Chen et al, 1999; Vaittinen and Hemminki, 2000). In men, the risk
of second breast cancer after a first breast cancer is much higher,
of the order of 100 (Dong and Hemminki, 2001; Auvinen et al,
2002), despite the overall pathology, natural history and hormonal
risk factors for sporadic and familial breast cancers showing
certain similarities for both genders; socioeconomic risk factors
also appear similar for male and female breast cancers (Hsing et al,
1998; Hemminki and Li, 2003; Hemminki et al, 2003b). Klinefelter
syndrome, gynaecomastia and testicular disease are additional
male risk factors (Hultborn et al, 1997; Lynch et al, 1999).
Heritable mutations predisposing to male breast cancer include
BRCA2, BRCA1 and, possibly, the androgen receptor gene (Lynch
et al, 1999; Liede et al, 2004). Accounting for some 15% of all cases,
BRCA2 mutations are the most common heritable factors in male
breast cancer, and, in addition to breast cancer, carriers have an
increased risk of prostate, pancreatic and stomach cancers and
melanomas (Liede et al, 2004). BRCA1 mutations are less common
in male than female breast cancer, and also affect prostate cancer
(Liede et al, 2004). Few studies have assessed the risk of second
cancers, other than breast cancer, among male breast cancer
patients and melanoma appears to the be the only tumour showing
an excess among men (Auvinen et al, 2002; Hemminki and
Granstrom, 2002).
In the present study, the risks of second primary neoplasms for
first male breast cancer, and for male breast cancer following any
other cancer are based on pooled data from 13 large cancer
registries, which are collaborating in studies on second primary
neoplasms. As a result, the study is two times larger than the
previous largest study (Auvinen et al, 2002). Since concordant
(breast–breast) first and second primaries are not registered in all
centres, we do not report on such cancers.
SUBJECTS AND METHODS
An international multicentre study of second primary cancers has
been initiated among second primary cancers. It is a collaboration
of large cancer registries operating for at least 25 years including
British Columbia, Manitoba and Saskatchewan (Canada), Singapore,
Slovenia, Norway, Denmark, Scotland, New South Wales (Australia),
Sweden, Finland, Iceland and Zaragoza (Spain). Data were
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including age and sex of the subject, diagnosis and date of the first
primary, follow-up for mortality and date and diagnosis of the
second primary, if any. Information was also obtained from each
cancer registry on the set of rules used for defining a second
primary cancer. As these differ between cancer registries, and also
over time, the International Association of Cancer Registries
(IACR)/International Agency for Research on Cancer (IARC) rules
on second primary cancers were adopted as a common set of rules
(Muir and Percy, 1991). Tumours were included according to the
recording practice of the participating centres, for example,
including histologically benign tumours of the central nervous
system and carcinoids at any sites. Nonmelanoma skin cancer
includes 53.9% basal and 46.1% squamous cell carcinomas and
other tumours; as second cancers, the proportion of these types is
49.6 and 50.4%, respectively. This was possible as all participating
cancer registries currently use the IACR/IARC rules, or a local set
of more extensive or detailed rules. The Swedish data have been
used in a previous study of male breast cancer (Dong and
Hemminki, 2001).
The follow-up time varied according to the available data from
the different registries. The follow-up time was longest, 1943–
1997, for the Danish and shortest, 1978–1998, for the Spanish data.
Observed numbers of male neoplasms were compared to the
expected number derived from the age, sex and calendar period-
specific cancer incidence rates in each of the cancer registries.
Standardised incidence ratios (SIR) adjusted for age, year and
registry were calculated using indirect standardisation methods.
Exact confidence intervals (CI) around the SIR were calculated
assuming a Poisson distribution for the observed number of
neoplasms. As a second type of analysis, we have calculated the SIR
for male breast cancer as a second primary after all other cancer
sites as a first primary.
RESULTS
The numbers of men diagnosed with a first primary breast cancer
are shown in Table 1 by various characteristics. A total of 3409
men was diagnosed, and of these 426 (12.5%) subsequently
developed a second primary neoplasm. More than half of all men
were over 65 years at diagnosis, as many as 25% were diagnosed
before year 1975, and the most common follow-up period was 1–4
years (41.1% of all men).
The SIRs for second neoplasms by length of follow-up are shown
in Table 2 for sites for which at least four cases were recorded in
the overall analysis. In the overall analysis, all malignancies were
increased by 34%. The highest SIRs were found for small intestine
(4.95) and myeloid leukaemia (3.42); among small intestinal
tumours, two were carcinoids, one was carcinoma and another one
was histologically unspecified. Other specific sites of increased
SIRs were the rectum (1.78), pancreas (1.93), (nonmelanoma) skin
(1.65) and prostate (1.61). Nonmelanoma skin tumours were in
excess only in the short follow-up period, o12 months after breast
cancer; liver cancer and leukaemias were increased only in the
middle follow-up period (1–9 years); pancreatic cancer was only
increased in the longest follow-up period (10þ years). Only
prostate cancer was increased in two follow-up periods.
The effect of diagnostic age for breast cancer on the risk
of subsequent neoplasms was analysed in Table 3. Stomach,
pancreatic and lung cancers were in excess among relatively young
breast cancer patients (diagnosed below age 56 years); larynx
cancer was increased in those diagnosed between 56 and 65 years.
The SIR for small intestinal cancer was 11.5 in males diagnosed at
66–74 years. Rectal and skin cancers were increased in old breast
cancer patients. For leukaemias, the histological type changed by
diagnostic age of breast cancer: myeloid leukaemia was in excess in
younger patients, whereas among subjects aged 475 years,
lymphoid leukaemia was seen in excess.
The effect of the calendar period of breast cancer diagnosis is
shown in Table 4. The overall risk of second primary neoplasms
was somewhat increasing throughout the study period from 1.29
(before year 1975) to 1.41 (1991þ). An excess of lung cancer was
limited to patients diagnosed at 1991þ, whereas skin tumours
were detected in those diagnosed in the early years of follow-up.
A total of 225 male breast cancers was recorded after any other
neoplasms (data not shown). No increase was found after any
individual site; after all lymphohaematopoietic neoplasms, the risk
for breast cancer was 1.80 (N¼18, 1.07–2.84). An excess of breast
cancer was diagnosed less than 12 months after lip cancer (SIR
Table 1 Characteristics of men diagnosed with first primary breast cancer
Second cancer status
a
Total Free from second cancer Have a second cancer
n % n % n %
Age at first cancer registration (years)
o56 617 20.7 60 14.1 677 19.9
56–65 706 23.7 101 23.7 807 23.7
66–74 799 26.8 152 35.7 951 27.9
75+ 861 28.9 113 26.5 974 28.6
Calendar period at first cancer registration
o1975 740 24.8 111 26.1 851 25
1975–1983 721 24.2 144 33.8 865 25.4
1984–1990 661 22.2 102 23.9 763 22.4
1991+ 861 28.9 69 16.2 930 27.3
Follow-up period
Less than 1 year 524 17.6 73 17.1 597 17.5
1–4 years 1248 41.8 153 35.9 1401 41.1
5–9 years 670 22.5 111 26.1 781 22.9
10+ years 541 18.1 89 20.9 630 18.5
Total 2983 100 426 100 3409 100
aCancer different from the first cancer.
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All Less than 12 months 1–9 years 10+ years
Cancer sites
(ICD 9th revision) Observed SIR 95% CI Observed SIR 95% CI Observed SIR 95% CI Observed SIR 95% CI
All malignant (140–208) 426 1.34 (1.22–1.47) 73 1.62 (1.27–2.03) 264 1.31 (1.16–1.48) 89 1.25 (1.01–1.54)
Oral cavity, pharynx (140–149) 8 0.93 (0.40–1.82) 1 0.78 (0.02–4.34) 7 1.25 (0.50–2.57) 0
Stomach (151) 22 1.09 (0.68–1.65) 4 1.24 (0.34–3.18) 12 0.92 (0.48–1.61) 6 1.53 (0.56–3.34)
Small intestine (152) 4 4.95 (1.35–12.7) 1 8.56 (0.21–47.7) 2 3.92 (0.47–14.2) 1 5.54 (0.14–30.9)
Colorectal (153, 154) 55 1.35 (1.02–1.76) 10 1.73 (0.83–3.19) 38 1.47 (1.04–2.02) 7 0.77 (0.31–1.58)
Colon (153) 25 1.05 (0.68–1.55) 4 1.19 (0.33–3.05) 17 1.13 (0.66–1.80) 4 0.75 (0.20–1.91)
Rectum (154) 30 1.78 (1.20–2.54) 6 2.48 (0.91–5.40) 21 1.96 (1.21–3.00) 3 0.80 (0.16–2.33)
Liver, gallbladder, bile ducts
(155–156, excluding 155.2)
6 1.07 (0.39–2.33) 0 6 1.70 (0.62–3.70) 0
Liver (155, excluding 155.2) 6 1.85 (0.68–4.02) 0 6 2.95 (1.08–6.41) 0
Pancreas (157) 18 1.93 (1.14–3.05) 4 2.97 (0.81–7.59) 8 1.35 (0.58–2.65) 6 2.95 (1.08–6.43)
Larynx (161) 7 1.80 (0.73–3.72) 1 1.73 (0.04–9.66) 4 1.59 (0.43–4.08) 2 2.53 (0.31–9.16)
Lung (162) 63 1.26 (0.96–1.61) 9 1.21 (0.55–2.30) 39 1.21 (0.86–1.65) 15 1.44 (0.81–2.37)
Melanoma of skin (172) 9 1.29 (0.59–2.45) 0 7 1.58 (0.64–3.26) 2 1.24 (0.15–4.46)
Other neoplasm of skin (173) 36 1.65 (1.16–2.29) 9 2.92 (1.34–5.54) 20 1.47 (0.90–2.27) 7 1.38 (0.56–2.85)
Prostate (185) 119 1.61 (1.34–1.93) 19 1.94 (1.17–3.02) 78 1.69 (1.34–2.11) 22 1.23 (0.77–1.87)
Bladder (188, 189.3, 189.4) 18 0.86 (0.51–1.36) 6 2.04 (0.75–4.45) 9 0.68 (0.31–1.29) 3 0.63 (0.13–1.84)
Kidney (189, excluding 189.3, 189.4) 7 0.85 (0.34–1.75) 2 1.73 (0.21–6.25) 2 0.38 (0.05–1.38) 3 1.63 (0.34–4.78)
Lymphohaematopoietic (200–208) 33 1.63 (1.12–2.29) 5 1.76 (0.57–4.10) 21 1.63 (1.01–2.50) 7 1.54 (0.62–3.18)
Lymphomas (200–202) 11 1.33 (0.66–2.37) 1 0.87 (0.02–4.84) 6 1.14 (0.42–2.47) 4 2.14 (0.58–5.48)
Non-Hodgkin’s lymphoma
(200, 202)
11 1.46 (0.73–2.62) 1 0.97 (0.02–5.42) 6 1.26 (0.46–2.74) 4 2.33 (0.64–5.97)
Multiple myeloma (203) 5 1.18 (0.38–2.74) 2 3.36 (0.41–12.1) 3 1.12 (0.23–3.28) 0
Leukaemias (204–208) 17 2.21 (1.29–3.54) 2 1.81 (0.22–6.55) 12 2.45 (1.27–4.28) 3 1.78 (0.37–5.20)
Lymphoid leukaemia (204) 7 1.86 (0.75–3.83) 0 6 2.51 (0.92–5.45) 1 1.21 (0.03–6.76)
Myeloid leukaemia (205) 8 3.42 (1.47–6.73) 1 3.02 (0.08–16.8) 6 3.98 (1.46–8.67) 1 1.98 (0.05–11.0)
SIR¼standardised incidence ratios; CI¼confidence interval; ICD¼International Classification of Diseases. Bold numerals show that 95% CI does not include 1.00.
Table 3 SIR for second malignancy after first male breast cancer diagnosed at different ages
Age at first cancer registration (years)
o56 56–65 66–74 75+
Cancer sites (ICD 9th revision) Observed SIR 95% CI Observed SIR 95% CI Observed SIR 95% CI Observed SIR 95% CI
All malignant (140–208) 60 1.62 (1.23–2.08) 101 1.18 (0.96–1.43) 152 1.39 (1.18–1.63) 113 1.32 (1.09–1.58)
Oral cavity, pharynx (140–149) 3 1.94 (0.40–5.66) 3 1.11 (0.23–3.25) 1 0.38 (0.01–2.13) 1 0.56 (0.01–3.13)
Stomach (151) 7 3.82 (1.54–7.87) 1 0.20 (0.00–1.11) 12 1.64 (0.85–2.87) 2 0.34 (0.04–1.21)
Small intestine (152) 1 7.67 (0.19–42.8) 0 3 11.50 (2.37–33.5) 0
Colorectal (153, 154) 5 1.10 (0.36–2.56) 12 1.11 (0.57–1.94) 16 1.15 (0.66–1.86) 22 1.93 (1.21–2.93)
Colon (153) 1 0.40 (0.01–2.20) 5 0.82 (0.26–1.90) 9 1.10 (0.50–2.09) 10 1.44 (0.69–2.64)
Rectum (154) 4 1.97 (0.54–5.06) 7 1.49 (0.60–3.08) 7 1.21 (0.49–2.50) 12 2.72 (1.41–4.76)
Liver, gallbladder, bile ducts (155–
156, excluding 155.2)
0 2 1.30 (0.16–4.69) 2 1.02 (0.12–3.70) 2 1.36 (0.16–4.92)
Liver (155, excluding 155.2) 0 2 2.16 (0.26–7.82) 2 1.77 (0.21–6.38) 2 2.52 (0.30–9.11)
Pancreas (157) 5 4.66 (1.51–10.9) 6 2.42 (0.89–5.27) 5 1.54 (0.50–3.59) 2 0.79 (0.10–2.86)
Larynx (161) 0 5 3.66 (1.19–8.54) 2 1.75 (0.21–6.32) 0
Lung (162) 13 2.03 (1.08–3.48) 18 1.14 (0.67–1.80) 18 1.03 (0.61–1.63) 14 1.33 (0.73–2.23)
Melanoma of skin (172) 0 3 1.38 (0.29–4.04) 3 1.52 (0.31–4.45) 3 2.37 (0.49–6.93)
Other neoplasm of skin (173) 2 0.90 (0.11–3.26) 5 0.95 (0.31–2.21) 14 2.00 (1.09–3.35) 15 2.07 (1.16–3.41)
Prostate (185) 9 1.47 (0.67–2.79) 26 1.48 (0.97–2.17) 53 1.95 (1.46–2.56) 31 1.35 (0.92–1.92)
Bladder (188, 189.3, 189.4) 2 0.85 (0.10–3.07) 2 0.35 (0.04–1.28) 8 1.12 (0.48–2.20) 6 1.04 (0.38–2.26)
Kidney (189, excluding 189.3, 189.4) 3 2.24 (0.46–6.55) 2 0.82 (0.10–2.95) 2 0.74 (0.09–2.66) 0
Lymphohaematopoietic
(200–208)
5 1.77 (0.58–4.14) 9 1.65 (0.75–3.13) 8 1.19 (0.51–2.35) 11 2.10 (1.05–3.75)
Lymphomas (200–202) 2 1.45 (0.18–5.25) 2 0.86 (0.10–3.09) 5 1.89 (0.61–4.41) 2 1.03 (0.12–3.72)
Non-Hodgkin’s lymphoma
(200, 202)
2 1.68 (0.20–6.06) 2 0.95 (0.12–3.44) 5 2.07 (0.67–4.83) 2 1.11 (0.13–4.01)
Multiple myeloma (203) 0 0 1 0.68 (0.02–3.79) 4 3.51 (0.96–8.99)
Leukaemias (204–208) 3 3.24 (0.67–9.47) 7 3.52 (1.42–7.25) 2 0.77 (0.09–2.77) 5 2.31 (0.75–5.39)
Lymphoid leukaemia (204) 1 2.28 (0.06–12.7) 2 2.00 (0.24–7.23) 0 4 3.78 (1.03–9.68)
Myeloid leukaemia (205) 1 3.50 (0.09–19.5) 4 6.53 (1.78–16.7) 2 2.50 (0.30–9.03) 1 1.55 (0.04–8.65)
SIR¼standardised incidence ratios; CI¼confidence interval; ICD¼International Classification of Diseases. Bold numerals show that 95% CI does not include 1.00.
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y5.37, N¼3, 1.11–15.7). Breast cancer was also increased 1–9 years
after prostate cancer (SIR 1.45, N¼48, 1.07–1.92) and after
multiple myeloma (SIR 3.77, N¼4, 1.03–9.65). There was no
overall increase in breast cancer after prostate cancer (SIR 1.19,
N¼56, 0.90–1.54).
DISCUSSION
In order to interpret the results of the present study, we need
to consider the treatment options that have been available
throughout the study period. In general, therapies for male
breast cancer have been adopted from female breast cancer, and
surgery and radiotherapy, usually in combination, have been the
main treatments throughout the study period (Buzdar, 2003;
Gennari et al, 2004) with chemotherapy increasing towards
the end.
The present data should be of high quality, as they were carefully
controlled by the participating, well-established cancer registries.
These pooled data are the largest data set used for the study of
male breast cancer. Nevertheless, chance associations consequent
on the multiple comparisons may be present and the findings
should be considered tentative.
The finding that two cancers were increased after each other,
irrespective of the order would represent suggestive evidence. For
example, non-Hodgkin’s lymphoma is increased after squamous
cell carcinoma of the skin in men and women, and a similar
association has been observed in the reverse order (Hemminki
et al, 2003a). Such a broad internal control is, however, usually
possible only for reasonably common malignancies of both
genders with good survival and reasonably similar age distribu-
tions. In the present study, prostate cancer was increased after
breast cancer, and breast cancer was increased after prostate
cancer; however, only in one follow-up period. BRCA2 (and to
some extent BRCA1) mutations could explain these findings.
Among other BRCA2-related male tumours, pancreatic cancer
showed a high risk after breast cancer (overall SIR 1.93) and
stomach cancer was increased in men who were diagnosed with
breast cancer before the age of 56 years; however, no increase was
observed for melanoma in contrast to findings from the SEER
study (Auvinen et al, 2002; Hemminki and Granstrom, 2002).
Radiotherapy and many chemotherapy agents cause DNA
damage, which may be related to the risk of subsequent neoplasms.
A trend with an increasing relative risk with follow-up time would
provide evidence for a relation between therapy for the primary
cancer and the risk of a second cancer in the present study
(Swerdlow et al, 2000). However, there was no increasing relative
risk with follow-up time for any neoplasm following male
breast cancer. Leukaemia risks were above unity throughout the
follow-up periods, and they were highest for myeloid leukaemia.
The only significant risk for pancreatic cancer was in the last
follow-up period, but the SIRs were above unity throughout the
follow-up periods; besides, therapy-induced pancreatic cancer is
probably rare (Swerdlow et al, 2000). An increased risk of
nonmelanoma skin cancer was only noted in the first follow-up
period, which may be due to surveillance effects or immunological
disturbances.
The sites at which increased overall SIRs were noted and which
were not related to the above conditions included the small
intestine and rectum. Increased SIRs were additionally noted for
liver, lung and laryngeal cancers and for multiple myeloma, when a
specific follow-up period or diagnostic age was considered. There
are no obvious common environmental risk factors for these
neoplasms. Some of the small intestinal tumours were carcinoids
and these types of tumours are often diagnosed incidentally and
more often among individuals with high socioeconomic status
(Hemminki and Li, 2001). The involvement of sites in the same
organ systems, gastrointestinal tract and respiratory system may
add some credibility to the findings.
The relative increase in all second neoplasms (breast excluded)
was a moderate 1.34, in marked contrast to second breast cancer,
which can be up to 100 (Auvinen et al, 2002; Hemminki and
Table 4 SIR for second malignancy after first male breast cancer diagnosed at different periods
Period at first cancer registration
o1975 1975–1983 1984–1990 1991+
Cancer sites (ICD 9th revision) Observed SIR 95% CI Observed SIR 95% CI Observed SIR 95% CI Observed SIR 95% CI
All malignant (140–208) 111 1.29 (1.06–1.55) 144 1.35 (1.13–1.59) 102 1.34 (1.10–1.63) 69 1.41 (1.10–1.78)
Oral cavity, pharynx (140–149) 1 0.36 (0.01–2.03) 4 1.40 (0.38–3.59) 3 1.53 (0.32–4.48) 0
Stomach (151) 9 1.01 (0.46–1.91) 10 1.66 (0.80–3.06) 3 0.89 (0.18–2.60) 0
Small intestine (152) 2 8.41 (1.02–30.4) 0 1 5.31 (0.13–29.6) 1 7.99 (0.20–44.5)
Colorectal (153, 154) 13 1.15 (0.61–1.96) 21 1.52 (0.94–2.33) 14 1.47 (0.80–2.46) 7 1.16 (0.47–2.39)
Colon (153) 6 0.97 (0.36–2.11) 8 0.97 (0.42–1.92) 10 1.74 (0.84–3.20) 1 0.27 (0.01–1.52)
Rectum (154) 7 1.36 (0.55–2.80) 13 2.34 (1.25–4.01) 4 1.05 (0.29–2.69) 6 2.53 (0.93–5.50)
Liver (155, excluding 155.2) 0 3 2.64 (0.54–7.71) 2 2.61 (0.32–9.44) 1 1.95 (0.05–10.9)
Pancreas (157) 7 2.32 (0.93–4.77) 6 1.87 (0.69–4.08) 4 2.06 (0.56–5.26) 1 0.87 (0.02–4.83)
Larynx (161) 2 1.93 (0.23–6.97) 1 0.73 (0.02–4.04) 3 3.24 (0.67–9.46) 1 1.86 (0.05–10.4)
Lung (162) 14 1.09 (0.60–1.83) 19 0.99 (0.60–1.55) 17 1.46 (0.85–2.34) 13 1.98 (1.05–3.39)
Melanoma of skin (172) 1 0.87 (0.02–4.85) 4 1.85 (0.50–4.72) 1 0.44 (0.01–2.47) 3 2.15 (0.44–6.30)
Other neoplasm of skin (173) 11 2.04 (1.02–3.66) 12 1.54 (0.80–2.69) 8 1.58 (0.68–3.11) 5 1.42 (0.46–3.32)
Prostate (185) 25 1.41 (0.91–2.08) 38 1.67 (1.18–2.29) 28 1.45 (0.97–2.10) 28 2.00 (1.33–2.90)
Bladder (188, 189.3, 189.4) 6 1.11 (0.41–2.41) 5 0.68 (0.22–1.59) 5 1.01 (0.33–2.36) 2 0.62 (0.07–2.24)
Kidney (189, excluding 189.3, 189.4) 3 1.28 (0.26–3.75) 3 1.15 (0.24–3.35) 0 1 0.79 (0.02–4.38)
Lymphohaematopoietic (200–208) 11 2.00 (1.00–3.58) 10 1.49 (0.71–2.74) 7 1.43 (0.58–2.95) 5 1.58 (0.51–3.70)
Lymphomas (200–202) 5 2.55 (0.83–5.95) 3 1.10 (0.23–3.23) 2 0.93 (0.11–3.35) 1 0.68 (0.02–3.81)
Non Hodgkin lymphoma (200, 202) 5 3.03 (0.98–7.06) 3 1.22 (0.25–3.55) 2 0.99 (0.12–3.59) 1 0.72 (0.02–4.03)
Multiple myeloma (203) 1 0.84 (0.02–4.66) 1 0.70 (0.02–3.93) 1 1.00 (0.02–5.55) 2 3.13 (0.38–11.3)
Leukaemias (204–208) 5 2.14 (0.70–5.00) 6 2.33 (0.86–5.07) 4 2.32 (0.63–5.95) 2 1.89 (0.23–6.84)
Lymphoid leukaemia (204) 4 3.42 (0.93–8.75) 2 1.59 (0.19–5.75) 1 1.21 (0.03–6.73) 0
Myeloid leukaemia (205) 1 1.60 (0.04–8.93) 4 4.85 (1.32–12.4) 2 3.52 (0.43–12.7) 1 3.08 (0.08–17.1)
SIR¼standardised incidence ratios; CI¼confidence interval; ICD¼International Classification of Diseases. Bold numerals show that 95% CI does not include 1.00.
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modest excess risk of second prostate cancer may amount to
equally many excess cases as second breast cancer. Excess cases are
also found for pancreatic and nonmelanoma skin tumours and for
leukaemias.
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